(firstQuint)Post-marketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.

.

 This is a multicenter, open label study to evaluate the safety and efficacy of add-on therapy with anticholinergics in OAB patients on mirabegron.

 The duration of the study period will be 54 weeks in total, comprising a 2-week screening period and a 52-week treatment period.

.

 Post-marketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.

@highlight

The objective of the study is to evaluate the safety and efficacy of add-on therapy with anticholinergics in patients with overactive bladder (OAB) on mirabegron.

